$4.26
+0.22
(+5.45%)▲
11.74%
Downside
Day's Volatility :11.74%
Upside
0.0%
74.18%
Downside
52 Weeks Volatility :79.01%
Upside
18.7%
Period | Elutia Inc | Index (Russel 2000) |
---|---|---|
3 Months | 24.93% | 0.0% |
6 Months | 18.66% | 0.0% |
1 Year | 199.26% | 0.0% |
3 Years | 199.26% | -22.3% |
Market Capitalization | 137.6M |
Book Value | - $2.27 |
Earnings Per Share (EPS) | -3.09 |
Wall Street Target Price | 10.0 |
Profit Margin | -261.08% |
Operating Margin TTM | -98.89% |
Return On Assets TTM | -29.16% |
Return On Equity TTM | 0.0% |
Revenue TTM | 25.0M |
Revenue Per Share TTM | 1.12 |
Quarterly Revenue Growth YOY | -0.8999999999999999% |
Gross Profit TTM | 19.2M |
EBITDA | -18.7M |
Diluted Eps TTM | -3.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.62 |
EPS Estimate Next Year | -1.1 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.27 |
What analysts predicted
Upside of 134.74%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 42.9M | - |
Net Income | -11.9M | - |
Net Profit Margin | -27.83% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.7M | ↓ 0.51% |
Net Income | -21.8M | ↑ 82.8% |
Net Profit Margin | -51.13% | ↓ 23.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 47.4M | ↑ 11.03% |
Net Income | -24.8M | ↑ 13.78% |
Net Profit Margin | -52.4% | ↓ 1.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 23.8M | ↓ 49.68% |
Net Income | -32.9M | ↑ 32.48% |
Net Profit Margin | -137.94% | ↓ 85.54% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 24.7M | ↑ 3.76% |
Net Income | -43.7M | ↑ 32.71% |
Net Profit Margin | -176.42% | ↓ 38.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.1M | ↑ 3.04% |
Net Income | -8.0M | ↑ 46.58% |
Net Profit Margin | -61.1% | ↓ 18.15% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.3M | ↓ 21.1% |
Net Income | -10.6M | ↑ 33.2% |
Net Profit Margin | -103.16% | ↓ 42.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.1M | ↓ 40.49% |
Net Income | -9.7M | ↓ 8.23% |
Net Profit Margin | -159.08% | ↓ 55.92% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.9M | ↓ 4.11% |
Net Income | -15.3M | ↑ 57.14% |
Net Profit Margin | -260.7% | ↓ 101.62% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.7M | ↑ 13.94% |
Net Income | -18.0M | ↑ 17.48% |
Net Profit Margin | -268.81% | ↓ 8.11% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.3M | ↓ 6.02% |
Net Income | -28.2M | ↑ 56.61% |
Net Profit Margin | -447.94% | ↓ 179.13% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 44.8M | - |
Total Liabilities | 99.9M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 82.8M | ↑ 84.96% |
Total Liabilities | 62.0M | ↓ 37.95% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 67.2M | ↓ 18.89% |
Total Liabilities | 53.6M | ↓ 13.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 68.8M | ↑ 2.49% |
Total Liabilities | 73.9M | ↑ 37.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 43.4M | ↓ 36.92% |
Total Liabilities | 82.0M | ↑ 11.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 60.6M | ↓ 11.93% |
Total Liabilities | 72.8M | ↓ 1.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.3M | ↓ 13.69% |
Total Liabilities | 74.5M | ↑ 2.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 54.6M | ↑ 4.3% |
Total Liabilities | 84.1M | ↑ 12.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.4M | ↓ 20.43% |
Total Liabilities | 82.0M | ↓ 2.41% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 35.4M | ↓ 18.57% |
Total Liabilities | 85.7M | ↑ 4.43% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 41.9M | ↑ 18.5% |
Total Liabilities | 106.2M | ↑ 24.03% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.2M | - |
Investing Cash Flow | -577.0K | - |
Financing Cash Flow | 8.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 85.95% |
Investing Cash Flow | -640.0K | ↑ 10.92% |
Financing Cash Flow | 51.0M | ↑ 539.39% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.6M | ↑ 16.25% |
Investing Cash Flow | -369.0K | ↓ 42.34% |
Financing Cash Flow | 6.9M | ↓ 86.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.9M | ↑ 40.24% |
Investing Cash Flow | -540.0K | ↑ 46.34% |
Financing Cash Flow | 9.0M | ↑ 30.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.4M | ↓ 54.45% |
Investing Cash Flow | -85.0K | ↓ 36.57% |
Financing Cash Flow | -19.0K | ↓ 100.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.4M | ↑ 0.0% |
Investing Cash Flow | -85.0K | ↑ 0.0% |
Financing Cash Flow | -19.0K | ↑ 0.0% |
Sell
Neutral
Buy
Elutia Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Elutia Inc | 50.0% | 18.66% | 199.26% | 199.26% | 199.26% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Elutia Inc | NA | NA | NA | -2.62 | 0.0 | -0.29 | NA | -2.27 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Elutia Inc | Buy | $137.6M | 199.26% | NA | -261.08% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Elutia Inc
Revenue is down for the last 2 quarters, 6.69M → 6.29M (in $), with an average decrease of 6.0% per quarter
Netprofit is down for the last 4 quarters, -9.74M → -28.18M (in $), with an average decrease of 43.7% per quarter
aziyo was created by highcape partners and tissue banks international with the mission of restoring health and mobility to the greatest number of patients. our vision for aziyo is to impact healthcare as the premier partner in innovation of new solutions that realize the potential of regenerative medicine. honoring the gift from those who selfishly give the precious gift of donation to those who receive it, we are committed to honoring the lives of these brave individuals and their families everyday. whether you need a traditional bone graft, a processed osteobiologic, or a custom musculoskeletal tissue product, aziyo is committed to innovating new solutions that help fulfill the promise of regenerative medicine. at aziyo, we foster a collaborative environment where we deliver best-in-class solutions and operational excellence to our customers each and every day.
Organization | Elutia Inc |
Employees | 54 |
CEO | Dr. C. Randal Mills Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$4.26
+5.45%
Keyarch Acquisition Corp
$4.26
+5.45%
Connexa Sports Technologies Inc
$4.26
+5.45%
Us Value Etf
$4.26
+5.45%
First Wave Biopharma Inc
$4.26
+5.45%
Global X Msci Next Emerging
$4.26
+5.45%
Fat Projects Acquisition Corp
$4.26
+5.45%
Capital Link Global Fintech
$4.26
+5.45%
Applied Uv Inc
$4.26
+5.45%